21st Austria weekly - Valneva Vienna Stock Exchange 29/12/2023 [pic1]Valneva: Valneva SE a specialty vaccine company today announced that the Company is modifying its financial guidance for 2023. Product sales remains unchanged as do anticipated R&D expenses. The €90 million to €110 of other income related proceeds from potential sale Company’s priority review voucher PRV which was previously expected before year-end now in early 2024.The previous included total revenues and between €220 €260 million. modified 2023 includes stated product revenue €130 €150 million on track achieve well expenses €60 €70 were recently reduced primarily driven by lower than costs closeout COVID-19 activities. Peter Bühler Chief Financial Officer
21st Austria weekly - Valneva Vienna Stock Exchange 29/12/2023 [pic1]Valneva: Valneva SE a specialty vaccine company today announced that the Company is modifying its financial guidance for 2023. Product sales remains unchanged as do anticipated R&D expenses. The €90 million to €110 of other income related proceeds from potential sale Company’s priority review voucher PRV which was previously expected before year-end now in early 2024.The previous included total revenues and between €220 €260 million. modified 2023 includes stated product revenue €130 €150 million on track achieve well expenses €60 €70 were recently reduced primarily driven by lower than costs closeout COVID-19 activities. Peter Bühler Chief Financial Officer
21st Austria weekly - Valneva Vienna Stock Exchange 29/12/2023 [pic1]Valneva: Valneva SE a specialty vaccine company today announced that the Company is modifying its financial guidance for 2023. Product sales remains unchanged as do anticipated R&D expenses. The €90 million to €110 of other income related proceeds from potential sale Company’s priority review voucher PRV which was previously expected before year-end now in early 2024.The previous included total revenues and between €220 €260 million. modified 2023 includes stated product revenue €130 €150 million on track achieve well expenses €60 €70 were recently reduced primarily driven by lower than costs closeout COVID-19 activities. Peter Bühler Chief Financial Officer
21st Austria weekly - Valneva Vienna Stock Exchange 29/12/2023 [pic1]Valneva: Valneva SE a specialty vaccine company today announced that the Company is modifying its financial guidance for 2023. Product sales remains unchanged as do anticipated R&D expenses. The €90 million to €110 of other income related proceeds from potential sale Company’s priority review voucher PRV which was previously expected before year-end now in early 2024.The previous included total revenues and between €220 €260 million. modified 2023 includes stated product revenue €130 €150 million on track achieve well expenses €60 €70 were recently reduced primarily driven by lower than costs closeout COVID-19 activities. Peter Bühler Chief Financial Officer